Beautiful Virgin Islands


Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill
Pfizer has made nearly $26bn (£21bn) in revenues in the first three months of the year, the bulk from its Covid-19 vaccine and new pill to treat the virus, prompting fresh accusations of pandemic profiteering.

Covid vaccines have saved many lives around the world and relieved the pressure on health systems, but Pfizer has faced criticism over its vaccine pricing and its refusal to waive patent protection to enable others to make the jab.

Last week 35 campaigners from Global Justice Now, Act-Up London, Just Treatment and Stop Aids protested against what they call pandemic profiteering, and delivered wheelbarrows full of fake money to Pfizer’s UK headquarters in Surrey on the day of the company’s annual shareholder meeting.

The New York-based firm posted total sales of $25.7bn in the first quarter, up 77% from a year earlier. Of this, $13.2bn came from the Comirnaty jab it developed with Germany’s BioNTech, driven by global uptake including jabs for children over the age of five, and booster doses. Pfizer and BioNTech are also seeking US approval for the vaccine’s use in children from six months to four years old.

A further $1.5bn came from Paxlovid, a Covid pill for people who are at high risk of severe disease, including hospitalisation or death. The treatment received emergency approval from the US regulator in late December and has been cleared by the UK and EU.

Pfizer has made tens of billions of dollars during the pandemic from its Covid-related products, as has the Boston-based biotech firm Moderna, which was loss-making until it started selling a Covid-19 vaccine.

Tim Bierley, a pharma campaigner at Global Justice Now, said: “Throughout the pandemic, Pfizer has refused to share its technology and knowhow. Instead, it has maintained monopoly control over its vaccine and treatment, keeping a chokehold on global supply.

“Despite calls from campaigners to allow countries in the global south to manufacture their own vaccines and treatments, Pfizer continues to put profit over people’s health. Pfizer’s revenues almost doubled last year and now it looks like the company’s coffers are set to swell even further. At a time when millions still don’t have access to vaccines or treatments for Covid-19, this continued pandemic profiteering is harrowing.”

Pfizer’s revenues last year doubled to $81.3bn, and it expects to make record sales of $98bn to $102bn this year, half of which will come from Covid products – $32bn from Comirnaty and $22bn from Paxlovid.

On the issue of sharing intellectual property, Pfizer said others would struggle to produce its mRNA vaccine – one of only two on the market – arguing that “it is not as simple as sharing the ‘recipe’”. Manufacture of its vaccine involves more than 280 materials from 86 suppliers in 19 countries.

Other companies, led by AstraZeneca, Britain’s biggest drugmaker, and Johnson & Johnson, a big US firm, went down the not-for-profit route and priced their Covid vaccines at cost during the pandemic. Towards the end of last year, AstraZeneca moved away from its not-for-profit pricing in new contracts, but insists that it is still offering “equitable pricing”.

Pfizer said it also offered tiered pricing, with the wealthier nations paying in the range of about the cost of a takeaway meal, while the upper-middle-income countries were offered doses at roughly half that price and the low- and lower-middle-income countries were offered doses at a not-for-profit price.

In March, the company struck an agreement with Unicef to supply up to 4m treatment courses of Paxlovid to 95 low- and middle-income countries at a not-for-profit price.

Moderna has promised not to enforce its coronavirus vaccine patents in some low- and middle-income countries.
Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Federal Reserve Chair Powell: "We are prohibited from owning Bitcoin and are not seeking any changes to that law."
A Democratic congresswoman with blue and black hair is having a meltdown over "President Musk."
A sizable group of unauthorized migrants is traveling through Mexico with the aim of reaching the USA before Trump assumes office.
Beatles Reunion Electrifies London: Paul McCartney and Ringo Starr Ignite O2 Arena with Surprise Performance
Starmer's Envoy Engages Trump Team as UK Seeks Strategic U.S. Partnership
Britain's Retail Rebound Falters as Black Friday Splurge Dissipates
Bank of Japan's Bold Reckoning: A Decade of Unconventional Policy Under Scrutiny
Republican Discord Threatens Government Shutdown Amid Holiday Season
French Retiree Dominique Pellico Convicted for Recruiting 72 Men to Assault Wife Over a Decade
Putin Defends War Strategy as Global Tensions Rise
Putin Claims Progress as Tensions Rise: Conflict in Ukraine Intensifies
Putin's Paradox: Claiming Strength Amidst Sanctions and Isolation
Water as a Weapon: The Contentious Struggle for Survival in Gaza
Syria's Future: A Fight for Democracy or Another Cycle of Oppression?
UK Considers Sending Troops to Ukraine: A Strategic Move or Intensifying The Proxy War?
Renewed ISIS Threat Puts Syria’s Cultural Heritage in Peril
Escalation in Moscow: High-Profile Assassination and International Tensions Intensify
North Korean Troops in Ukraine: A New Cold War Frontier?
Ukraine's Bold Move: High-Stakes Assassination of Russian General in Moscow
Dubai's Technological Leap: Brain Chips and AI Board Members by 2025
Tragedy Strikes Wisconsin School as Shooting Claims Lives of Teacher and Student
UK's Calculated Gamble: Balancing Defense Aid to Ukraine and Domestic Demands
UK Intensifies Stranglehold on Russian Oil, but Does It Dampen Putin’s Resolve?
British Voter Endorsement of Reeves's Bold Tax Strategy
Nicola Sturgeon Warns of 'Toxic' Discourse: The Perils of Polarisation in Modern Politics
Levelling Down: How the Conservatives Underspent on Regional Revitalization
Alleged Chinese Espionage: The Entangled Web Beyond Prince Andrew
Starmer Navigates Diplomatic Tightrope Amid Chinese Espionage Revelations Involving Prince Andrew
Balancing Democracy and Disorder: The Trial of a Milkshake Incident
Royal Mail Enters New Chapter Under Czech Ownership
UK Companies Slash Jobs Amid Economic Strain
Kemi Badenoch Rekindles Flat Tax Debate Amid Inheritance Tax Uproar
Rewiring Whitehall: New Cabinet Secretary's Mandate for Change
Legal Battle Revives: Lucy Letby Seeks Fresh Appeal as Expert Evidence Faces Scrutiny
Accusations Fly as UK-China Relations Spark Tension Within British Politics
The Delicate Dance of Devolution: As English Council Elections Face Delays
The Alleged Chinese Spy at the Heart of British Royal Circles: Yang Tengbo Unmasked
Prince Andrew Withdraws from Royal Christmas Amidst Chinese Espionage Scandal
EU Takes Legal Action Against UK Over Allegedly Neglected Rights of EU Citizens
Disaster Strikes: Oil Spill in the Black Sea and Cyclone Devastation in Mayotte
Oil Tanker Disaster in the Kerch Strait: A Confluence of Environmental Catastrophe and Geopolitical Tensions
Olaf Scholz’s Gamble: The Collapse of Germany’s Coalition Government and the Path to Early Elections
Keir Starmer's 'Sycophantic' Tone: Tensions Rise Over UK-China Relations
Trump Recognizes Partial Advances in Ceasefire Attempts in Ukraine Conflict
UK Navigates Complex Global and Domestic Challenges Amid Security, Environmental, and Health Concerns
Tragic Loss of Fashion Visionary: Isak Andic's Enduring Legacy Beyond Mango
UK's CPTPP Gamble: A Strategic Leap Toward the Indo-Pacific
Mango Founder Isak Andic Dies in Tragic Accident
Disney’s Dangerous Power Play: How Bob Iger's Personal Agenda Could Cost His Company Billions
ABC's $15 Million Settlement: A Turning Point in Media Defamation Battles
×